Jazz Pharmaceuticals layoffs, on the record
Every job cut, severance charge and restructuring Jazz Pharmaceuticals reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 2,800 to approximately 2,890.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 2,800 | December 31, 2023 |
| 10-K for 2024 | approximately 2,800 | December 31, 2024 |
| 10-K for 2025 | approximately 2,890 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryRestructuring costs were incurred in 2022, which the 2023 SG&A discussion compares against; no restructuring charge is reported for 2023.
Word for word“Selling, general and administrative expenses decreased in 2023 compared to 2022, primarily due to the loss on disposal of Sunosi of $40.8 million, restructuring costs of $22.1 million and GW related integration costs of $21.1 million incurred in 2022, together with a reduction in costs related to program terminations of $19.1 million and in compensation related expenses, partially offset by an impairment of facility assets of $61.7 million in 2023.” 10-K for 2023
Our summaryRestructuring expenses were recorded in research and development in 2022 and none in 2023.
Word for word“We incurred restructuring costs of $10.3 million in 2022.” 10-K for 2023
Jazz Pharmaceuticals filed 1 restructuring notice (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Jazz Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.